Annual message from the Vielight CEO, Dr. Lew Lim
2018 was another wonderful year for us. Every year, we take another step forward to further our mission of improving human lives with innovation. Some discoveries would not have been possible without the work of certain research collaborators. I would like to briefly acknowledge some of them here.
We obtained strong evidence through electroencefalography, EEG, (by measuring electrical signals) that the human brain responds significantly to the way Vielight delivers photobiomodulation, PBM. Our Neuro Gamma wearable device was put to test in a double-bind study on healthy brains. This study was headed by Dr. Reza Zomorrodi from the Centre of Addiction and Mental Health, University of Toronto. Significant elevation in the power spectrum and connectivity were observed in the alpha, beta and gamma bands, along with suppression in the delta and theta bands. The study is currently being reviewed for publication in a high impact journal.
Moving on, Dr. Linda Chao of the University of California San Francisco replicated the earlier cognitive assessment results in the Saltmarche et al dementia/Alzheimer study in a controlled pilot study. She also observed improved blood perfusion in the default mode network hubs through functional Magnetic Resonance Imaging, fMRI, and ASL over 12 weeks. These provided further evidence of the brain’s significant response to the Neuro Gamma photobiomodulating device.
In the world of meditation, Dr. Sanjay Manchanda, Dr. Jay Sanguinetti and Dr. Jeffery Martin, collaborated with us on the use of the prototype of the Neuro Pro device for advanced meditators. The device is capable of inducing any pulse frequency to the brain. We observed rapid entry into desired altered meditative states with induced oscillations specific to the person. We are planning a controlled meditation study (which is inherently challenging) to understand this phenomenon better and allow for easy replication.
Dr. Jay Sanguinetti at the Dr. Vincent Clark lab at the University of New Mexico conducted a controlled study of cognitive performance and observed extraordinary improvement, a large effect size. Dr. Sanguinetti and his team used asynchronous pulsing Neuro Gamma devices. This feature is built in all our commercial units. The researchers discovered that the device has to pulse asynchronously (out-of-phase) to induce improvement in cognitive performance. Currently, we are in the process of finding out why the brain behaves in this way. This study has taught us that there is no standard way of delivering photobiomodulation to the brain and expecting it to work the same way for everyone. We are learning that the frequency and phase synchrony matter a great deal in affecting cognitive performance.
In the field of neurofeedback (NFB), Penijean Gracefire, NFB clinician and innovator, presented Quantitative Electroencephalography or QEEG images on how the dysfunctional brain responds to different pulse frequencies delivered by a Neuro headset. She demonstrated that each individual has his or her own sweet spots for induced oscillation to help with significant brain recovery. It suggests that Vielight photobiomodulation may be of profound help to neurofeedback practitioners seeking quick and effective personalized therapies. We plan on expanding research in this area.
In sports, professional athletes reported greater endurance and recovery during training. They also experienced better on-demand competitive physical and mental performance with Vielight devices. Much research has already been done in the application of PBM for sports, so this is not new. What sets Vielight apart is the effectiveness, portability and ease of use. Clinicians have measured improved oxygenation of the blood cells with the Vielight 655 Prime intranasal PBM device. We plan to research this area further in 2019.
I would like to make a special mention of Dr. Margaret Naeser and Dr. Liisa Laakso, as they continue their clinical research in brain photobiomodulation, incorporating Vielight devices into their research protocols.
What is in store for 2019? We continue to improve on our products and invent new ones to expand on achievable outcomes in the fields of photobiomodulation and phototherapy. I hope that we can have beta versions of our new Neuro Pro headset by the end of 2019. We should also have more data from the various clinical studies that are in progress now. We are particularly excited about the potential outcomes of the studies on Alzheimer’s, cognition, traumatic brain injury, autism, sports performance and meditation. There should be new data that helps to provide deeper explanations of the mechanisms of the effects of photobiomodulation on the brain, blood and other systems.
Lastly, but most importantly, all of us at Vielight would like to thank everyone for your continued support. I expect that some of these discoveries could change in 2019.